Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: Firas Tarish Clear advanced filters

  • It remains challenging to characterise somatic copy number alterations (SCNAs) in tumors and the surrounding tissues with spatial and single-cell resolution. Here, the authors develop the scCUTseq approach to characterise SCNAs from single cells in multi-region prostate cancer samples and identify pseudo-diploid cells and subclones.

    • Ning Zhang
    • Luuk Harbers
    • Nicola Crosetto
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-17

  • Spatial heterogeneity in prostate cancer can contribute to its resistance to androgen deprivation therapy (ADT). Here, the authors analyse prostate cancer samples before and after ADT using Spatial Transcriptomics, and find heterogeneous pre-treatment tumour cell populations and stromal cells that are associated with resistance.

    • Maja Marklund
    • Niklas Schultz
    • Joakim Lundeberg
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-18

  • Heterogeneity within tumors presents a challenge to cancer treatment. Here, the authors investigate transcriptional heterogeneity in prostate cancer, examining expression profiles of different tissue components and highlighting expression gradients in the tumor microenvironment.

    • Emelie Berglund
    • Jonas Maaskola
    • Joakim Lundeberg
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-13

  • Tumours with homologous recombination (HR) defects become sensitive to PARPi. Here, the authors show that androgen receptor (AR) regulates HR and AR inhibition activates the PARP pathway in vivo, thus inhibition of both AR and PARP is required for effective treatment of high risk prostate cancer.

    • Mohammad Asim
    • Firas Tarish
    • Thomas Helleday
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-10